Mezzion Pharma Co.Ltd (140410) - Net Assets
Based on the latest financial reports, Mezzion Pharma Co.Ltd (140410) has net assets worth ₩15.51 Billion KRW (≈ $10.51 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩98.92 Billion ≈ $67.04 Million USD) and total liabilities (₩83.41 Billion ≈ $56.53 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Mezzion Pharma Co.Ltd assets under control for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩15.51 Billion |
| % of Total Assets | 15.68% |
| Annual Growth Rate | -9.54% |
| 5-Year Change | -72.62% |
| 10-Year Change | -67.44% |
| Growth Volatility | 50.51 |
Mezzion Pharma Co.Ltd - Net Assets Trend (2012–2025)
This chart illustrates how Mezzion Pharma Co.Ltd's net assets have evolved over time, based on quarterly financial data. Check how tangible is Mezzion Pharma Co.Ltd's equity to evaluate the tangible quality of the company's equity base.
Annual Net Assets for Mezzion Pharma Co.Ltd (2012–2025)
The table below shows the annual net assets of Mezzion Pharma Co.Ltd from 2012 to 2025. For live valuation and market cap data, see 140410 stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | ₩17.19 Billion ≈ $11.65 Million |
-62.67% |
| 2024-12-31 | ₩46.06 Billion ≈ $31.22 Million |
-25.03% |
| 2023-12-31 | ₩61.44 Billion ≈ $41.64 Million |
+134.16% |
| 2022-12-31 | ₩26.24 Billion ≈ $17.78 Million |
-58.21% |
| 2021-12-31 | ₩62.79 Billion ≈ $42.55 Million |
+10.53% |
| 2020-12-31 | ₩56.81 Billion ≈ $38.50 Million |
+32.64% |
| 2019-12-31 | ₩42.83 Billion ≈ $29.03 Million |
-25.28% |
| 2018-12-31 | ₩57.32 Billion ≈ $38.84 Million |
+7.80% |
| 2017-12-31 | ₩53.17 Billion ≈ $36.03 Million |
+0.68% |
| 2016-12-31 | ₩52.81 Billion ≈ $35.79 Million |
-15.55% |
| 2015-12-31 | ₩62.54 Billion ≈ $42.38 Million |
-1.26% |
| 2012-12-31 | ₩63.34 Billion ≈ $42.92 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Mezzion Pharma Co.Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 921.1% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | ₩195.32 Billion | 1135.96% |
| Total Equity | ₩17.19 Billion | 100.00% |
Mezzion Pharma Co.Ltd Competitors by Market Cap
The table below lists competitors of Mezzion Pharma Co.Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Taeyoung Engineering & Construction Co.,Ltd.
KO:009410
|
$318.03 Million |
|
R Systems International Limited
NSE:RSYSTEMS
|
$318.13 Million |
|
Claros Mortgage Trust Inc
NYSE:CMTG
|
$318.30 Million |
|
Caledonia Mining Corporation Plc
F:9CD1
|
$318.36 Million |
|
Dividend Growth Split Corp
TO:DGS
|
$317.95 Million |
|
International CSRC Investment Holdings Co Ltd
TW:2104
|
$317.83 Million |
|
Taiwan Fire & Marine Insurance Co Ltd
TW:2832
|
$317.60 Million |
|
Wholetech System Hitech Ltd
TWO:3402
|
$317.59 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Mezzion Pharma Co.Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 46,062,511,800 to 17,194,549,710, a change of -28,867,962,090 (-62.7%).
- Net loss of 34,928,862,370 reduced equity.
- New share issuances of 4,356,831,720 increased equity.
- Other factors increased equity by 1,704,068,560.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-34.93 Billion | -203.14% |
| Share Issuances | ₩4.36 Billion | +25.34% |
| Other Changes | ₩1.70 Billion | +9.91% |
| Total Change | ₩- | -62.67% |
Book Value vs Market Value Analysis
This analysis compares Mezzion Pharma Co.Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 97.04x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 22.99x to 97.04x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩2388.50 | ₩54900.00 | x |
| 2017-12-31 | ₩2233.74 | ₩54900.00 | x |
| 2018-12-31 | ₩2225.90 | ₩54900.00 | x |
| 2019-12-31 | ₩1639.86 | ₩54900.00 | x |
| 2020-12-31 | ₩2129.43 | ₩54900.00 | x |
| 2021-12-31 | ₩2351.53 | ₩54900.00 | x |
| 2022-12-31 | ₩981.23 | ₩54900.00 | x |
| 2023-12-31 | ₩2076.71 | ₩54900.00 | x |
| 2024-12-31 | ₩1537.30 | ₩54900.00 | x |
| 2025-12-31 | ₩565.76 | ₩54900.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Mezzion Pharma Co.Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -203.14%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -441.61%
- • Asset Turnover: 0.08x
- • Equity Multiplier: 5.70x
- Recent ROE (-203.14%) is below the historical average (-48.31%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 3.77% | 27.75% | 0.13x | 1.06x | ₩-3.95 Billion |
| 2015 | 6.75% | 28.29% | 0.14x | 1.65x | ₩-2.03 Billion |
| 2016 | -24.59% | -148.38% | 0.09x | 1.82x | ₩-18.27 Billion |
| 2017 | -27.99% | -266.42% | 0.08x | 1.39x | ₩-20.20 Billion |
| 2018 | -32.93% | -98.89% | 0.25x | 1.31x | ₩-24.61 Billion |
| 2019 | -54.29% | -122.82% | 0.32x | 1.37x | ₩-27.53 Billion |
| 2020 | -24.34% | -48.30% | 0.38x | 1.33x | ₩-19.51 Billion |
| 2021 | -21.66% | -51.03% | 0.32x | 1.34x | ₩-19.88 Billion |
| 2022 | -138.33% | -118.13% | 0.57x | 2.06x | ₩-38.92 Billion |
| 2023 | -20.72% | -40.13% | 0.34x | 1.50x | ₩-18.87 Billion |
| 2024 | -42.28% | -226.17% | 0.12x | 1.61x | ₩-24.08 Billion |
| 2025 | -203.14% | -441.61% | 0.08x | 5.70x | ₩-36.65 Billion |
Industry Comparison
This section compares Mezzion Pharma Co.Ltd's net assets metrics with peer companies in the Pharmaceuticals industry.
Industry Context
- Industry: Pharmaceuticals
- Average net assets among peers: $97,337,363,880
- Average return on equity (ROE) among peers: -4.09%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Mezzion Pharma Co.Ltd (140410) | ₩15.51 Billion | 3.77% | 5.38x | $317.97 Million |
| Sam Chun Dang Pharm. Co. Ltd (000250) | $114.32 Billion | 10.17% | 0.61x | $2.43 Billion |
| DongKoo Bio&Pharma Co. Ltd (006620) | $100.12 Billion | 9.32% | 0.55x | $23.04 Million |
| NatureCell Co.Ltd (007390) | $61.42 Billion | -19.02% | 0.11x | $890.24 Million |
| Sam-A Pharm. Co. Ltd (009300) | $160.90 Billion | 5.47% | 0.08x | $51.21 Million |
| Kyung Dong Pharmaceutical Co. Ltd (011040) | $226.71 Billion | 8.88% | 0.27x | $79.21 Million |
| WooGene B&G Co. Ltd (018620) | $27.27 Billion | -46.89% | 2.12x | $43.55 Million |
| Oscotec Inc (039200) | $53.05 Billion | -8.21% | 0.44x | $574.18 Million |
| EstechPharma Co. Ltd (041910) | $128.58 Billion | 3.07% | 0.05x | $42.35 Million |
| Komipharm International Co. Ltd (041960) | $66.46 Billion | -6.71% | 0.73x | $277.38 Million |
| Eagle Veterinary Technology Co.Ltd (044960) | $34.55 Billion | 3.02% | 0.33x | $25.83 Million |
About Mezzion Pharma Co.Ltd
Mezzion Pharma Co.,Ltd. engages in the development, licensing, and commercialization of drugs for the treatment of vascular diseases. It is developing Udenafil, a PDE5 inhibitor to treat erectile dysfunction, benign prostatic hyperplasia, pulmonary arterial hypertension, overactive bladder, hepatic portal hypertension, and chronic obstructive pulmonary diseases. The company was formerly known as … Read more